JamesLRileyMDJD

Physician

Dr. Riley is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Barry Law SchoolJD, law, 2003 - 2006
Massachusetts General HospitalResidency, Anesthesiology, 1980 - 1982
Loma Linda University Health Education ConsortiumInternship, Internal Medicine, 1979 - 1980
Loma Linda University School of MedicineClass of 1979

US Patent on TIVA (total intravenous anesthesia) US6186977B1 US Patent and Trade Office, 2001
Founder of JLR Medical Group, now US Anesthesia Partners 1989

PubMed

855 citations
Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
Michael C. Milone, Jonathan D. Fish, Carmine Carpenito, Richard G. Carroll, Gwendolyn K. Binder
Molecular Therapy. 2009-08-01
649 citations
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
Carmine Carpenito, Michael C. Milone, Raffit Hassan, Jacqueline C. Simonet, Mehdi Lakhal
Proceedings of the National Academy of Sciences of the United States of America. 2009-03-03
561 citations
PD-1 signaling in primary T cells.
James L. Riley
Immunological Reviews. 2009-05-01

Journal Articles

CAR T Cells for Infection, Autoimmunity and Allotransplantation
James Riley, MD, Nature

Restoring HIV-1 Specific T Cell ImmunityNational Cancer Institute2010–2012
Novel Immune Assessment And Mouse CoreNational Institute Of Allergy And Infectious Diseases2009–2012
ImmunologyNational Institute Of Allergy And Infectious Diseases2009–2011
PD-1 Signaling In T Cells During Chronic Viral InfectionNational Institute Of Allergy And Infectious Diseases2008–2011
Core--Immunology FacilityNational Institute Of Allergy And Infectious Diseases2008
Lentiviral Redirected T Cells For B Cancer ImmunotherapyNational Cancer Institute2007–2008
Development Of Tumor Based Antigen Presenting CellsNational Cancer Institute2007–2008
Engineering Innate T Cell Resistance To HIV InfectionNational Institute Of Allergy And Infectious Diseases2005–2008
Regulation Of Human T Cell Activation By The CD28 FamilyNational Institute Of Allergy And Infectious Diseases2004–2008
Expansion Of HIV Infected T Cells For ImmunotherapyNational Institute Of Allergy And Infectious Diseases2004–2005